Fagron reported a solid first-quarter revenue of €263.4 million in 2026, marking a 10.3% increase on a reported basis and 15.0% at constant exchange rates (CER). The growth was supported by acquisitions, including the recent Pharmavit purchase in the Netherlands, and strong performance in Latin America, which saw 10.4% organic growth at CER. All regions contributed positively, with EMEA growing 2.8% and North America-Pacific 0.6% at CER despite some normalization in GLP-1 related revenues. The company expects mid- to high-single digit organic sales growth and a REBITDA margin around 20% for the full year, with stronger performance anticipated in the second half as integration of acquisitions progresses smoothly.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
